search
Back to results

Treatment of Neonatal Abstinence Syndrome (HOMENOW)

Primary Purpose

Neonatal Abstinence Syndrome

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Methadone
Diluted Deodorized Tincture of Opium
Sponsored by
Eastern Maine Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Neonatal Abstinence Syndrome focused on measuring Neonatal Abstinence Syndrome, Methadone, Diluted Deodorized Tincture of Opium, dDTO, Phenobarbital

Eligibility Criteria

1 Day - 6 Days (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Evidence of opioid withdrawal clinically as defined by 2 NAS scores >8 or 1 NAS score >12 over a 4 to 8 hour time period, AND
  • Gestation >=35 weeks at entry defined by best obstetrical and physical exam criteria, AND
  • Medically stable condition, other than in opioid withdrawal, in the opinion of the attending neonatologist, AND EITHER,
  • Meconium or urine drug screen positive for opioids on mother or newborn, OR
  • Known maternal prescription of opioids for chronic pain management during at least the last trimester of pregnancy, OR
  • Known maternal prescription of opioids for treatment of addiction, OR
  • Suspected or admitted abuse with opioid drugs
  • Infants of mothers with a medical or psychiatric diagnosis will not be excluded, unless the maternal diagnosis precludes informed consent

Exclusion Criteria:

  • Gestation <35 weeks at entry defined by best obstetrical and physical exam criteria.
  • Hypoglycemia, hypomagnesaemia, or hypocalcaemia until corrected.
  • Serious medical illness such as sepsis, pneumonia, hyperthyroidism, meningitis, intracranial hemorrhage, perinatal depression, or respiratory failure requiring admission to the NICU.
  • Evidence of major congenital anomalies or genetic syndromes that impact the neonatal course.

Sites / Locations

  • Eastern Maine Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1 (Phenobarbital and Methadone)

2 (Phenobarbital and Diluted Deodorized Tincture of Opium)

Arm Description

The following is a dosing guide for methadone: The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours. For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score: NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose ≥16 0.15 mg/kg/dose Maximum dose of methadone will be 0.15 mg/kg/dose. After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours. If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm.

The following is a dosing guide for dDTO: The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours. The starting dose will be determined using a sliding scale in response to the last NAS score before starting. NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day ≥16 0.8 mg/kg/day The maximum dose of DTO will be 0.8 mg/kg/day. After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level. If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm.

Outcomes

Primary Outcome Measures

Length of Treatment With Opioid Medication
Up to 12 months

Secondary Outcome Measures

Full Information

First Posted
January 27, 2011
Last Updated
November 5, 2013
Sponsor
Eastern Maine Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT01723722
Brief Title
Treatment of Neonatal Abstinence Syndrome
Acronym
HOMENOW
Official Title
Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Eastern Maine Medical Center

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study compares treatment of Neonatal Abstinence Syndrome (NAS) with two different drugs for the difference in the length of treatment. This is a randomized, open-label comparison of phenobarbital and methadone versus phenobarbital and diluted deodorized tincture of opium (dDTO) where phenobarbital is the initial drug used to stabilize neonatal withdrawal.
Detailed Description
a.Procedures: NAS scoring is currently done on infants meeting the inclusion criteria [IDD 29:070]. NAS scores are initially done every 2 hours for 24 hours and then every 4 hours when awake or before feeding for the duration of observation or treatment. i. NAS scores may indicate more than withdrawal. Conditions such as colic, reflux, or baseline irritability may influence the baseline scores. Decisions made based on the NAS scores should take into account these factors and the baseline for the infant. b.Emergence of symptom, dosing, and initiation of treatment: Withdrawal is defined as at least 2 NAS scores >8 or 1 NAS score >12. Once withdrawal has emerged, the infant will be given: i. Phenobarbital 20 to 30 mg/kg to load divided in up to 3 doses over 24 hours and maintenance phenobarbital should be started at 2.5 mg/kg/dose administered Q 12h, 12 hours after the loading dose is ended. NAS scoring is continued and if scores remain <8 for a minimum of 5 days after starting phenobarbital, the infant is eligible for discharge. ii. If after phenobarbital treatment has been started, at least 2 NAS scores >8 or 1 NAS score >12, then a phenobarbital level will be drawn and a mini-load calculated to reach a level of 30 mg/dl. If withdrawal is not controlled or re-emerges after the mini-load dose, the infant will be randomized to one of the two arms of the study - methadone or dDTO. iii. Twins will be randomized together to the same arm. iv. Randomization will be stratified into mothers on narcotic treatment >3 months and those not in treatment or <3 months. Randomization will be done in blocks of 10 for each stratum. v. For both drugs, the neonatal preparation will be used. vi. The following is a dosing guide for methadone: The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours - standardized eventually to 0900 and 2100. For the first 24 hours, doses will be prescribed every 6 hours for 4 doses, using a sliding scale in response to the last NAS score: NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose >16 0.15 mg/kg/dose Maximum loading dose of methadone will be 0.15 mg/kg/dose Q 6 hour After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. Subsequently, PRN doses of 0.05 mg/kg/dose may be given every 6 hours for scores >8 X 2 and added to the next 24 hour's doses, divided every 12 hours, until NAS scores are consistently <8 for 48 hours. If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm. vii. The following is a dosing guide for dDTO: The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours - standardized eventually to 0400, 0800, 1200, 1600, 2000, 0000. The starting dose is determined by using a sliding scale in response to the last NAS score before starting: NAS Score dDTO dose 8-11 0.1 mg/kg/day 12-15 0.15 mg/kg/day >16 0.2 mg/kg/day For next day, the maintenance dose will return to the previous dose and given in 6 divided doses given Q 4 hours. iv. For either methadone or dDTO, dosing will be held at this level and weaning will be resumed when the infant has NAS scores <8 for 48 hours. e. Holding of doses: Methadone or dDTO will be held for poor feeding, respiratory depression, or somnolence at any time in the protocol. f. Behavioral assessment: Behavioral assessment will be done by two methods. The first by actigraphy and the second by NINS, both during the second week of weaning. The latter will be done prior to a scheduled phenobarbital dose. g. Formula: A 24 kcal/ounce formula should be fed initially using either standard formula or by adding breast milk fortifier. During the weaning period, when weight gain is >30 grams/day for at least 2 days, formula will be changed to 20 kcal/ounce and weight gain monitored. If not sustained, then formula should be changed back to 24 kcal/ounce.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neonatal Abstinence Syndrome
Keywords
Neonatal Abstinence Syndrome, Methadone, Diluted Deodorized Tincture of Opium, dDTO, Phenobarbital

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1 (Phenobarbital and Methadone)
Arm Type
Active Comparator
Arm Description
The following is a dosing guide for methadone: The neonatal concentration is 1 mg/ml of methadone. It is administered orally every 12 hours. For the first 24 hours, doses will be prescribed every 6 hours using a sliding scale in response to the last NAS score: NAS Score Methadone dose 8-11 0.05 mg/kg/dose 12-15 0.1 mg/kg/dose ≥16 0.15 mg/kg/dose Maximum dose of methadone will be 0.15 mg/kg/dose. After the first 24 hours of treatment, the total methadone dose will be summed and that dose divided into two doses, given 12 hours apart. For the following 24 hours, additional doses may be given every 6 hours as needed and added to the next 24 hour's doses divided every 12 hours, until NAS scores are consistently <8 for 48 hours. If at any pointthe maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the dDTO arm.
Arm Title
2 (Phenobarbital and Diluted Deodorized Tincture of Opium)
Arm Type
Active Comparator
Arm Description
The following is a dosing guide for dDTO: The neonatal concentration is 1:24 dilution for a concentration of 0.4%, equivalent to 0.4 mg/ml of morphine. It is administered orally every 4 hours. The starting dose will be determined using a sliding scale in response to the last NAS score before starting. NAS Score Starting dDTO dose 8-11 0.4 mg/kg/day 12-15 0.6 mg/kg/day ≥16 0.8 mg/kg/day The maximum dose of DTO will be 0.8 mg/kg/day. After the first 24 hours of treatment, if the NAS scores are still ≥8, the dose will be increased to the next level. If at any point the maximum dose of methadone is reached and withdrawal is not controlled, then in the opinion of two neonatologists the patient can be crossed-over to the methadone arm.
Intervention Type
Drug
Intervention Name(s)
Methadone
Other Intervention Name(s)
Dolophine
Intervention Description
Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
Intervention Type
Drug
Intervention Name(s)
Diluted Deodorized Tincture of Opium
Other Intervention Name(s)
Laudanum
Intervention Description
Concentration is 1:24 dilution for a concentration of 0.4%
Primary Outcome Measure Information:
Title
Length of Treatment With Opioid Medication
Description
Up to 12 months
Time Frame
Up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
6 Days
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Evidence of opioid withdrawal clinically as defined by 2 NAS scores >8 or 1 NAS score >12 over a 4 to 8 hour time period, AND Gestation >=35 weeks at entry defined by best obstetrical and physical exam criteria, AND Medically stable condition, other than in opioid withdrawal, in the opinion of the attending neonatologist, AND EITHER, Meconium or urine drug screen positive for opioids on mother or newborn, OR Known maternal prescription of opioids for chronic pain management during at least the last trimester of pregnancy, OR Known maternal prescription of opioids for treatment of addiction, OR Suspected or admitted abuse with opioid drugs Infants of mothers with a medical or psychiatric diagnosis will not be excluded, unless the maternal diagnosis precludes informed consent Exclusion Criteria: Gestation <35 weeks at entry defined by best obstetrical and physical exam criteria. Hypoglycemia, hypomagnesaemia, or hypocalcaemia until corrected. Serious medical illness such as sepsis, pneumonia, hyperthyroidism, meningitis, intracranial hemorrhage, perinatal depression, or respiratory failure requiring admission to the NICU. Evidence of major congenital anomalies or genetic syndromes that impact the neonatal course.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark S. Brown, MD
Organizational Affiliation
Eastern Maine Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Eastern Maine Medical Center
City
Bangor
State/Province
Maine
ZIP/Postal Code
04401
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
34231914
Citation
Zankl A, Martin J, Davey JG, Osborn DA. Opioid treatment for opioid withdrawal in newborn infants. Cochrane Database Syst Rev. 2021 Jul 7;7(7):CD002059. doi: 10.1002/14651858.CD002059.pub4.
Results Reference
derived

Learn more about this trial

Treatment of Neonatal Abstinence Syndrome

We'll reach out to this number within 24 hrs